168 related articles for article (PubMed ID: 25886699)
21. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
22. Erdheim-Chester disease: MR imaging, anatomic, and histopathologic correlation of orbital involvement.
De Abreu MR; Chung CB; Biswal S; Haghighi P; Hesselink J; Resnick D
AJNR Am J Neuroradiol; 2004 Apr; 25(4):627-30. PubMed ID: 15090356
[TBL] [Abstract][Full Text] [Related]
23. Unusual orbital involvement in Erdheim Chester disease: a radiological diagnosis.
Arora A; Sharma S; Pushker N; Kashyap S; Bakhshi S
Orbit; 2012 Oct; 31(5):338-40. PubMed ID: 22631449
[TBL] [Abstract][Full Text] [Related]
24. Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers.
Ruan GJ; Goyal G; Shah MV; Cohen-Aubart F; Amoura Z; Straetmans N; Benameur N; Haroche J; Go RS;
Pancreas; 2021 Jan; 50(1):e6-e8. PubMed ID: 33370037
[No Abstract] [Full Text] [Related]
25. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib.
Schirmer JH; Thorns C; Moosig F; Holle JU
Rheumatology (Oxford); 2015 Oct; 54(10):1932-4. PubMed ID: 26139656
[No Abstract] [Full Text] [Related]
26. Orbital and eyelid manifestations of xanthogranulomatous diseases.
Vick VL; Wilson MW; Fleming JC; Haik BG
Orbit; 2006 Sep; 25(3):221-5. PubMed ID: 16987770
[TBL] [Abstract][Full Text] [Related]
27. Dramatic response to encorafenib in a patient with Erdheim-Chester disease harboring the BRAF
Wada F; Hiramoto N; Yamashita D; Hara S; Furukawa Y; Ishii J; Nagata K; Nannya Y; Ogawa S; Ishikawa T
Am J Hematol; 2021 Aug; 96(8):E295-E298. PubMed ID: 33971044
[No Abstract] [Full Text] [Related]
28. Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.
Roeser A; Cohen-Aubart F; Breillat P; Miyara M; Emile JF; Charlotte F; Donadieu J; Amoura Z; Haroche J
Haematologica; 2019 Nov; 104(11):e502-e505. PubMed ID: 30923093
[No Abstract] [Full Text] [Related]
29. CLINICAL PROBLEM-SOLVING. From Dancing to Debilitated.
Houston BA; Miller PE; Rooper LM; Scheel PJ; Gelber AC
N Engl J Med; 2016 Feb; 374(5):470-7. PubMed ID: 26840137
[No Abstract] [Full Text] [Related]
30. [Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement].
Berthe P; Rouzic N; Daelman L; Jacobzone C; Espitia A; Cohen-Aubart F; Haroche J; Émile JF; Lorleac'h A
Rev Med Interne; 2020 Jun; 41(6):413-417. PubMed ID: 32113636
[TBL] [Abstract][Full Text] [Related]
31. Orphan drug approval for Erdheim-Chester disease.
The Lancet Haematology
Lancet Haematol; 2017 Dec; 4(12):e562. PubMed ID: 29195598
[No Abstract] [Full Text] [Related]
32. Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation.
Bentel JM; Thomas MA; Rodgers JJ; Arooj M; Gray E; Allcock R; Fermoyle S; Mancera RL; Cannell P; Parry J
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28455460
[TBL] [Abstract][Full Text] [Related]
33. Regression of orbital and choroidal metastases from melanoma after treatment with vemurafenib.
Ngo E; Hutchins LF; Gardner JM; Uwaydat SH
Can J Ophthalmol; 2014 Apr; 49(2):e49-52. PubMed ID: 24767240
[No Abstract] [Full Text] [Related]
34. A 72-year old female with multiple supra- and infratentorial dural masses.
Kirschenbaum D; Woernle C; Haralambieva E; Marques Maggio E; Bernays R; Camenisch U; Rushing EJ
Brain Pathol; 2018 Nov; 28(6):1023-1024. PubMed ID: 30536772
[No Abstract] [Full Text] [Related]
35. Pulmonary Erdheim-Chester disease successfully treated with vemurafenib.
Shen KN; Chang L; Niu N; Li J; Cao XX
Ann Hematol; 2024 Feb; 103(2):673-675. PubMed ID: 37924362
[No Abstract] [Full Text] [Related]
36. Dendritic cell disorders: matters of lineage and clinical drug testing in rare diseases.
Arceci RJ
J Clin Oncol; 2015 Feb; 33(5):383-5. PubMed ID: 25534378
[No Abstract] [Full Text] [Related]
37. Comparative Study of Clinical, Pathological, Radiological, and Genetic Features of Patients With Adult Ocular Adnexal Xanthogranulomatous Disease, Erdheim-Chester Disease, and IgG4-Related Disease of the Orbit/Ocular Adnexa.
McKelvie P; McNab AA; Hardy T; Rathi V
Ophthalmic Plast Reconstr Surg; 2017; 33(2):112-119. PubMed ID: 26882062
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
Cohen Aubart F; Emile JF; Maksud P; Galanaud D; Cluzel P; Benameur N; Aumaitre O; Amoura Z; Haroche J
Br J Haematol; 2018 Jan; 180(1):150-153. PubMed ID: 27711968
[No Abstract] [Full Text] [Related]
39. A case of Erdheim-Chester disease with bilateral orbital involvement.
Wu Z; Yan J; Hong W; Yuan Y; Dai L
Yan Ke Xue Bao; 2001 Sep; 17(3):163-7. PubMed ID: 12567744
[TBL] [Abstract][Full Text] [Related]
40. Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.
Mazor RD; Manevich-Mazor M; Kesler A; Aizenstein O; Eshed I; Jaffe R; Pessach Y; Goldberg I; Sprecher E; Yaish I; Gural A; Ganzel C; Shoenfeld Y
BMC Med; 2014 Dec; 12():221. PubMed ID: 25434739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
